HGH vs Survodutide
FDA Approved vs Extensively Studied
monitor Mechanism-based · 55% Both HGH and Survodutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
HGH Survodutide
Weight 22,124 Da ~4,500 Da
Half-life 3-4 hours (SC), 20-30 minutes (IV) Approximately 6 days (109-115 hours)
Chain 191 amino acids 29 amino acids
Type Single-chain polypeptide with two disulfide bridges Peptide with fatty acid acylation
Key Benefits
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
Survodutide
01 Superior weight loss vs monotherapy (14.9% at 46 weeks)
02 Once-weekly convenient dosing
03 Proven efficacy in obesity, MASH, and Type 2 diabetes
04 62% MASH improvement in clinical trials
Dosing Protocols
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
Survodutide
0.6mg starting, titrate up to 3.6-6.0mg weekly / Once weekly (same day each week)
Obesity - Conservative Start 0.6mg titrated over 24 weeks Once weekly with 4-week intervals
Obesity - Standard Protocol 3.6-6.0mg Once weekly
MASH Treatment 2.4-4.8mg Once weekly
Type 2 Diabetes 0.3-2.7mg Once weekly
Side Effects
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
Survodutide
Nausea (40-66%)
Diarrhea (25-49%)
Vomiting (15-41%)
Slight heart rate increase (mean 2-5 bpm)
Contraindications
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Not recommended in pregnancy or breastfeeding
Use contraception during treatment
Research Evidence
HGH Survodutide
Status FDA Approved Extensively Studied
References 4 studies 3 studies
Latest 2024 —
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.